Synaffix and Hummingbird Bioscience have entered into a licensing agreement that it is hoped will enable Hummingbird Bio to develop an antibody drug conjugate (ADC) programme using Synaffix technology. Under the terms of the agreement, Synaffix will be eligible to receive up to $150 million, including upfront and milestone payments, plus royalties on net sales. […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!